Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046222 · ClinicalTrials.gov registry record · Phase 2
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
A Phase 2 study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome, sponsored by NS Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT06046222: Recruiting Phase 2 study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome, sponsored by NS Pharma.
NCT06046222 is a Phase 2 study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome that is actively recruiting participants, run by NS Pharma. The registered enrollment target is 45 participants, below the 621-participant average among 3 other Eosinophilic Granulomatosis With Polyangiitis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06046222, a Phase 2 study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome, is actively recruiting participants, sponsored by NS Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Primary Outcome
The proportion of subjects in remission (oral glucocorticoid \[OGC\] 4.0) at Week 28 of the study treatment period. Definition of remission (OGC 4.0): BVAS of 0 AND OGC dose of prednisolone/prednisone ≤4 mg/day
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NS-229
Study Locations (20)
Other
- CHU Nice - Nice
- Hopital Cochin - Paris
- Chu Rangueil - Toulouse
- Istituto Auxologico Italiano IRCCS - Milan
- Fondazione Policlinico Universitario Campus Bio-Medico - Roma
- Azienda Provinciale per i Servizi Sanitari Provincia Autonoma Trento - Trento
- Azienda Ospedaliera Universitaria Integrata Verona - Verona
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
Ontario
- St Joseph's Healthcare Hamilton - Hamilton
- University of Toronto - Toronto
Colorado
- National Jewish Health - Denver
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT06046222 shows while recruiting
NCT06046222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 621-participant average among 3 other Eosinophilic Granulomatosis With Polyangiitis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Eosinophilic Granulomatosis With Polyangiitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06046222 names 20 study sites across 12 states, led by Other, Ohio, Ontario.
Frequently Asked Questions
What is clinical trial NCT06046222 about?
NCT06046222 is a clinical study titled "Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis". This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
What is the current status of trial NCT06046222?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2023-12-20. Estimated completion is 2026-07.
What conditions does trial NCT06046222 study?
This clinical trial studies the following conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome.
What interventions are being tested in trial NCT06046222?
The interventions under investigation include: Placebo (DRUG), NS-229 (DRUG).
Who is sponsoring clinical trial NCT06046222?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046222 being conducted?
This trial has 20 study locations across Colorado, Minnesota, Ohio, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Granulomatosis With Polyangiitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI